July 22, 2025

Optimizing TACE Method Selection for Patients with Postoperative Recurrence of Hepatocellular Carcinoma Based on ALBI Score

Key Points

ALBI grade is a significant prognostic factor in patients with recurrent hepatocellular carcinoma.
Among ALBI grade II-III patients, those receiving DEB-TACE had a longer overall survival than those undergoing cTACE.
This analysis included 239 postoperative HCC patients treated with either DEB-TACE or cTACE from 2016 to 2024.
The findings suggest that TACE method selection based on ALBI grade can impact survival outcomes.

Abstract

Abstract Objectives To evaluate transarterial chemoembolization (TACE) selection for postoperative hepatocellular carcinoma (HCC) patients based on albumin-bilirubin (ALBI) grade. Methods This retrospective study analyzed 239 HCC patients with postoperative recurrence treated with drug-eluting bead TACE (DEB-TACE) or conventional TACE (cTACE) from January 2016 to December 2024. Cox regression identified survival predictors, and patients were stratified for survival analysis. Results This study included a total of 239 patients with a median follow-up time of 27 months, including 118 cases of DEB-TACE and 121 cases of cTACE. Multivariate analysis suggested that AFP (p = 0.002), albumin (p = 0.003), and ALBI grade (p p p p > 0.05). Conclusion ALBI grade is a key prognostic factor for recurrent HCC. DEB-TACE may improve survival in ALBI II–III patients, whereas either method is suitable for ALBI grade I.

KI fragen

Bookmark

View Full Paper